ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2024
A study to compare the efficacy of neoadjuvant chemotherapy in locally advanced human epidermal growth factor receptor 2 overexpressing breast cancer.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel insights into phase angle in breast cancer - stage-specific associations between body composition and metabolic age.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This prospective single institutional study was conducted to compare the efficacy of the two different neoadjuvant chemotherapy (NACT) regimens in human epidermal growth factor receptor 2 (Her2neu) overexpressing non metastatic breast cancer. Materials and methods: Patients randomly assigned into two arms in a 1:1 ratio. Arm A received NACT containing docetaxel, doxorubicin, and cyclophosphamide (TAC) regimen. Arm B received NACT containing docetaxel, carboplatin, and trastuzumab (TCH) regimen. Patients underwent surgical intervention following completion of 6 cycles of NACT. Postoperative histopathological reports were compared in terms of pathological response. Results: 122 patients (Arm A = 61; Arm B = 61) analysed. The mean breast tumor size was 7.724 cm and 7.896 cm in Arm A and Arm B, respectively, at diagnosis and clinical staging. After 6 cycles of NACT, the mean breast tumor size in Arm A and Arm B was 3.495 cm and 3.711 cm, respectively. The Arm A and Arm B exhibited 22.9% and 40.9% of pathological complete response (pCR), respectively, with statistically significant difference (p = 0.033). All patients experienced varying degrees of bone marrow suppression. Grade 2 or 3 chemotherapy induced nausea and vomiting was 37.7% and 23% in Arm A and Arm B, respectively, without statistically significant difference (p = 0.076). 14.8% and 4.9% of patients exhibited febrile neutropenia in Arm A and Arm B, respectively, without statistically significant differences (p = 0.067). Conclusion: TCH exhibited greater pCR with tolerable adverse reactions in Her2neu overexpressing breast cancer compared to TAC regimen as NACT. Therefore, TCH regimen should be considered for node positive Her2neu overexpressing breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.